Indaptus Therapeutics (INDP) Action Cours

Indaptus Therapeutics Inc, trading under the ticker INDP, is a biotechnology company based in New York City, United States. The company, which went public via IPO on September 7, 2012, currently employs six full-time staff members. Indaptus operates in the health care sector, specifically within the biotechnology industry. The company is engaged in pre-clinical research focused on developing curative cancer immunotherapies for patients with unresectable or metastatic solid tumors and lymphomas. Its therapeutic approach involves targeting specific tumor or viral antigens. The company's lead candidate, Decoy20, is in pre-clinical development. Indaptus' platform is founded on the hypothesis that effective anti-tumor immunotherapy requires the activation of both innate and adaptive cellular immunity within tumors and immune organs. The company utilizes a multi-targeted approach involving bacterial pathogen-associated molecular patterns (PAMPs) delivered intravenously through attenuated and killed, intact but non-pathogenic bacteria. This method targets the liver, spleen, and leaky vasculature of tumors, aiming to produce immune activation in immune organs and sites commonly associated with primary and metastatic cancer, as well as hepatitis B virus (HBV) infection. The company's website is https://indaptusrx.com/.